×
About 22,810 results

ALLMedicine™ Hematopoietic Stem Cell Transplantation Center

Research & Reviews  7,695 results

Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on ...
https://doi.org/10.1093/labmed/lmac074
Laboratory Medicine; Puglianini OC, Peker D et. al.

Aug 13th, 2022 - Although several decades have passed since the description of myeloproliferative neoplasms (MPN), many aspects of their pathophysiology have not been elucidated. In this review, we discuss the mutational landscape of patients with essential thromb...

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation
https://clinicaltrials.gov/ct2/show/NCT04531046

Aug 12th, 2022 - Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy directed against CD19 which has been approved for the treatment of relapse/refractory diffuse large B-cell lymphoma DLBCL and primary mediastinal large B-cell ly...

Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation
https://clinicaltrials.gov/ct2/show/NCT03000244

Aug 12th, 2022 - Background: Patients who survive more than 3 years after allogeneic hematopoietic stem cell transplantation (HCT) have a high probability of being cured from their underlying disease; however, mortality rates remain 4 to 9-fold higher than the gen...

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT04023526

Aug 12th, 2022 - AML is a heterogeneous disease characterized by uncontrolled clonal expansion of hematopoietic progenitor cells. As the most common form of acute leukemia, AML accounts for the largest number of annual deaths from leukemia. Over 95 percent (%) of ...

Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
https://clinicaltrials.gov/ct2/show/NCT00092235

Aug 12th, 2022 - Background: Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune disorder that occurs following allogeneic hematopoietic stem cell transplantation (alloHSCT). It is characterized by immune dysregulation, immunodefic...

see more →

Guidelines  15 results

American Society of Hematology 2021 guidelines for sickle cell disease: stem cell trans...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945587
Blood Advances; Kanter J, Liem RI et. al.

Sep 29th, 2021 - Sickle cell disease (SCD) is a life-limiting inherited hemoglobinopathy that results in significant complications and affects quality of life. Hematopoietic stem cell transplantation (HSCT) is currently the only curative intervention for SCD; howe...

Veno-occlusive Disease in HSCT Patients: Consensus-based Recommendations for Risk Asses...
https://doi.org/10.1097/TP.0000000000003569
Transplantation Bonifazi F, Sica S et. al.

Dec 5th, 2020 - Variation in clinical practice affects veno-occlusive disease management, mainly in patients who undergo allogeneic hematopoietic stem cell transplantation. Disputes about diagnostic criteria, treatment, and prophylaxis, due to the lack of high-qu...

Sinusoidal obstruction syndrome.
https://doi.org/10.1016/j.clinre.2020.03.019
Clinics and Research in Hepatology and Gastroenterology; de Lédinghen V, Villate A et. al.

Apr 8th, 2020 - Sinusoidal obstruction syndrome (SOS), previously known as veno-occlusive disease, is characterized by concentric and non-thrombotic obstruction of the sinusoid and central vein lumen with no identified primitive or thrombotic hepatic vein lesions...

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormyc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394968
Haematologica Tissot F, Agrawal S et. al.

Dec 25th, 2016 - The European Conference on Infections in Leukemia (ECIL) provides recommendations for diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematologic malignancies or he...

Recommendations on hematopoietic stem cell transplantation for inherited bone marrow fa...
https://doi.org/10.1038/bmt.2015.117
Bone Marrow Transplantation; Peffault de Latour R, Peters C et. al.

Jun 9th, 2015 - Allogeneic hematopoietic stem cell transplantation (HSCT) offers the potential to cure patients with an inherited bone marrow failure syndrome (IBMFS). However, the procedure involves the risk of treatment-related mortality and may be associated w...

see more →

Drugs  19 results see all →

Clinicaltrials.gov  1,040 results

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT04023526

Aug 12th, 2022 - AML is a heterogeneous disease characterized by uncontrolled clonal expansion of hematopoietic progenitor cells. As the most common form of acute leukemia, AML accounts for the largest number of annual deaths from leukemia. Over 95 percent (%) of ...

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00574496

Aug 12th, 2022 - OUTLINE: Patients are stratified according to response to prior therapy and risk factors (those with presence of all 3 risk factors and failed primary therapy or primary progressive disease vs. patients who relapse more than 100 days after an auto...

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation
https://clinicaltrials.gov/ct2/show/NCT04531046

Aug 12th, 2022 - Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy directed against CD19 which has been approved for the treatment of relapse/refractory diffuse large B-cell lymphoma DLBCL and primary mediastinal large B-cell ly...

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
https://clinicaltrials.gov/ct2/show/NCT05027945

Aug 12th, 2022 - Background: In 2019, investigators at the National Institutes of Health defined a new disease syndrome named VEXAS: Vacuoles in bone marrow cells, E1 enzyme mutations, X-linked, Autoinflammatory, Somatic syndrome. This syndrome is characterized by...

BMS-986253 in Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT05148234

Aug 12th, 2022 - Background: The myelodysplastic syndromes (MDS) are a group of clonal bone marrow neoplasms characterized by ineffective hematopoiesis, cytopenia, and high risk for transformation to acute myeloid leukemia (AML). MDS is primarily a disease of the ...

see more →

News  355 results

Fourth Patient Cleared of HIV After Stem Cell Transplant for Blood Cancer
https://www.medscape.com/viewarticle/978169

Jul 28th, 2022 - MONTREAL ― A 66-year-old US man has become the world's fourth known HIV patient to show complete clearance of the virus after being treated for acute myelogenous leukemia with an allogeneic hematopoietic stem cell transplantation from a naturally ...

Short-Course or Extended Antibiotics in Febrile Neutropenia?
https://www.medscape.com/viewarticle/977939

Jul 26th, 2022 - Short-course antibiotics are sufficient for most patients, concludes an open-label trial that compared a 3-day course of antibiotics with an extended course for patients with febrile chemotherapy-induced neutropenia of unknown origin. Carbapenem a...

If Nuclear Disaster Strikes, US Hematologists Stand Ready
https://www.medscape.com/viewarticle/977010

Jul 12th, 2022 - For many Americans – especially those too young to know much about the Cold War or Hiroshima – Russia's invasion of Ukraine might mark the first time they've truly considered the dangers of nuclear weapons. But dozens of hematologists in the Unite...

Similar Survival, Less Toxicity With Decitabine vs Chemo in AML
https://www.medscape.com/viewarticle/975438

Jun 12th, 2022 - Older, fit patients with acute myeloid leukemia (AML) pretreated with a 10-day regimen of decitabine (Dacogen) prior to allogeneic hematopoietic stem cell transplantation had similar overall survival compared with those receiving conventional inte...

Novel gene therapy offers hope for some lymphomas
https://www.mdedge.com/hematology-oncology/article/255338/b-cell-lymphoma/novel-gene-therapy-offers-hope-some-lymphomas
Heidi Splete

Jun 9th, 2022 - Lisocabtagene maraleucel, a novel chimeric antigen receptor (CAR) T-cell product, evoked a clinical response in patients with relapsed or refractory large B-cell lymphoma in a pilot study presented at the annual meeting of the American Society of.

see more →